Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q2 2023 vs. Q1 2023
How the institutions holding Innate Pharma SA changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 397.1K | 235.3K | −161.8K (−40.7%) |
| Value | $1.13M | $735.6K | −$392.9K (−34.8%) |
New holders (3)
Institutions that held Innate Pharma SA at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Exchange Traded Concepts, LLC | 42,431 | $133.2K | 0.00% |
| Citadel Advisors LLC | 13,281 | $41.7K | 0.00% |
| Rhumbline Advisers | 205 | $643 | 0.00% |
Sold out (3)
Institutions that held Innate Pharma SA at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Bank of America Corp | 46,749 | $133.2K |
| Susquehanna International Group, LLP | 13,315 | $37.8K |
| Royal Bank of Canada | 124 | $0 |